[
    " in the membrane preparation was quantified using Dye Reagent Concentrate (manufactured by Bio-Rad Laboratories, Inc.) with bovine serum albumin (manufactured by Sigma-Aldrich Corp.) as a standard.</p>1-2 Receptor Binding Experiment[<sup>3</sup>H]Citalopram binding was measured according to the method of Owens et al. [Owens M.J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997)]. Specifically, 50 \u00b5l of [<sup>3</sup>H]citalopram (final concentration: approximately 2 nM) diluted with a SERT buffer, 149 \u00b5l of the h-SERT/CHO membrane preparation (40 \u00b5g/well in terms of the amount of the protein), and 1 \u00b5l of a solution of a test drug dissolved in dimethyl sulfoxide were mixed to prepare 200 \u00b5l in total of a solution. This solution was reacted at room temperature for 60 minutes and then rapidly filtered by suction at a low pressure through glass fiber filter paper coated with a 0.05% aqueous polyethyleneimine solution. The glass fiber filter paper was washed twice with 250 \u00b5l of a SERT buffer and then transferred to a glass vial containing 4 ml of ACS-II (manufactured by Amersham Biosciences). Radioactivity remaining on the filter paper was measured using a liquid scintillation counter. The amount of [<sup>3</sup>H]citalopram bound in the presence of 1 \u00b5M clomipramine was used as the amount of [<sup>3</sup>H]citalopram bound non-specifically.\nAn IC<sub>50</sub> value was calculated according to the Hill analysis [see Hill A.V., J. Physiol., 40, 190-200 (1910)]. A h-SERT binding inhibition constant (Ki) was calculated according to the equation: h-SERT binding inhibition constant (Ki)=IC<sub>50</sub>/((1+S/Kd) wherein S represents the concentration of [<sup>3</sup>H]citalopram added; and the Kd value represents the dissociation constant of [<sup>3</sup>H]citalopram, wherein the Kd value used was the value (2.16 nM) calculated by a saturation binding experiment separately conducted using the same cell membrane as above.\nA smaller value of the h-SERT binding inhibition constant Ki means a higher human serotonin reuptake inhibitory effect.</p>Test Example 2[<sup>3</sup>H]8-OH-DPAT Binding Test for Evaluating Affinity for Human Serotonin 1A Receptor2-1 Cells Used and Preparation of Membrane PreparationCHO cells containing a human serotonin 1A receptor (h-5-HT<sub>1A</sub>) expressed therein (h-5-HT<sub>1A</sub>/CHO) were used in the experiment. The cells were cultured in F12 containing 10% FCS, 500 \u00b5g/ml Geneticin, and 100 U/ml penicillin-100 \u00b5g/ml streptomycin (all manufactured by Sigma-Aldrich Corp.) in a 5% CO<sub>2</sub> incubator. The membrane preparation was prepared according to the method of Yabuuchi et al<sup>3)</sup>. Specifically, the cells were dissociated/collected using 50 mM Tris-HCl (pH=7.4). The resulting cells were homogenized using a Teflon (registered trademark) homogenizer and then centrifuged (48,000xg, 20 min, 4\u00b0C). The pellet was resuspended in an appropriate amount of 50 mM Tris-HCl (pH=7.4) and stored at -80\u00b0C until use. The amount of the protein in the membrane preparation was quantified using Dye Reagent Concentrate (manufactured by Bio-Rad Laboratories, Inc.) with bovine serum albumin (manufactured by Sigma-Aldrich Corp.) as a standard.</p>2-2 Receptor Binding ExperimentThe experiment was conducted according to the method of Yabuuchi et al. [Yabuuchi K. et al., Biogenic Amines, 18, 319-328 (2004)]. 50 \u00b5l of [<sup>3</sup>H]8-OH-DPAT (final concentration: 0.5 nM), 1 \u00b5l of a test drug solution, and 149 \u00b5l of the h-5-HT<sub>1A</sub>/CHO membrane preparation (25 \u00b5g/well in terms of the amount of the protein) were added to a buffer solution containing 50 mM Tris-HCl (pH=7.4) and 4 mM CaCl<sub>2</sub>, and 200 \u00b5l in total of the reaction solution was used in measurement. The reaction solution was reacted at room temperature for 30 minutes and then rapidly filtered by suction at a low pressure through glass fiber filter paper. The glass fiber filter paper was washed twice with 250 \u00b5l of 50 mM Tris-HCl (pH=7.4) and then added to a counting vial containing 4 ml of ACS-II (manufactured by Amersham Biosciences). Receptor binding radioactivity remaining on the filter paper was measured using a liquid scintillation counter. The amount of [<sup>3</sup>H]8-OH-DPAT bound in the presence of 10 \u00b5M 8-OH-DPAT was used as the amount of [<sup>3</sup>H]8-OH-DPAT bound non-specifically.\nAn IC<sub>50</sub> value was calculated according to the Hill analysis [see Hill A.V., J. Physiol., 40, 190-200 (1910)]. A h-5-HT<sub>1A</sub> binding inhibition constant (Ki) was calculated according to the equation: h-5-HT<sub>1A</sub> binding inhibition constant (Ki)=IC<sub>50</sub>/(1+S/Kd) wherein S represents the concentration of [<sup>3</sup>H]8-OH-DPAT added; and the Kd value represents the dissociation constant of [<sup>3</sup>H]8-OH-DPAT, wherein the Kd value used was the value (1.28 nM) calculated by a saturation binding experiment separately conducted using the same cell membrane as above.\nA smaller value of the h-5-HT<sub>1A</sub> binding inhibition constant Ki means higher affinity for human serotonin 1A receptors.</p>The benzylpiperidine compounds of the present invention obtained in Examples were subjected to the tests of Test Examples 1 and 2. The results are shown in Table 6. These test results demonstrated that the benzylpiperidine compound of the present invention or the pharmaceutically acceptable salt thereof not only has a human serotonin reuptake inhibitory effect in combination with binding affinity for human 5-HT1A receptors but also has a high human serotonin reuptake inhibitory effect.</p>[Table 6]Compound (Example No.)Test Example 1: h-SERT binding inhibition constant (Ki) [nM]Test Example 2: h-5-HT<sub>1A</sub> binding inhibition constant (Ki) [nM]10.874.520.701240.794.261.27272.74.682.83.793.113104.219116.43.8129.223137.48.6148.555153.235162.927174.030186.2295193.029202.457</p>Test Example 3CYP2D6 Inhibition Screening Test3-1 MaterialsDiclofenac was purchased from Sigma-Aldrich Corp., and Pooled of Human Liver Microsomes was purchased from Xenotech, LLC.</p>3-2-1 Preparation of 0.5 M Potassium Phosphate Buffer (pH 7.4)150 mL of a 0.5 M monopotassium phosphate solution and 700 mL of a 0.5 M dipotassium phosphate solution were mixed to adjust pH 7.4.</p>3-2-2 Preparation of 165 mM Magnesium Chloride SolutionMagnesium chloride hexahydrate was dissolved at a concentration of 3.35 g (MgCl<sub>2</sub>\u00b76H<sub>2</sub>O)/100 mL in distilled water.</p>3-2-3 Preparation of Human Liver Microsome Solution150 \u00b5L of Pooled Human Liver Microsomes (20 mg/ml), 12 mL of a 0.5 M potassium phosphate buffer, 1.2 mL of a 165 mM magnesium chloride solution, and 34.65 mL of distilled water were mixed.</p>3-2-4 Preparation of 13 mM \u03b2-NADPH Solution\u03b2-NADPH was dissolved at a concentration of 11.75 mg/mL in distilled water.</p>3-2-5 Preparation of Substrate SolutionDiclofenac was dissolved at a concentration of 2.0 mM in DMSO and then diluted 200-fold with distilled water.</p>3-3 Experimental Procedures1. A 10 mM DMSO solution of a test drug was serially diluted 5-fold with DMSO for 4 serial dilutions to prepare 10, 2, 0.4, and 0.08 mM DMSO solutions.2. Each test drug solution of the step 1. and DMSO were separately diluted 96-fold with ",
    "e suspended in a buffer solution containing 0.1 mM CaCl<sub>2</sub> and 1 mM MgCl<sub>2</sub> in PBS (hereinafter, referred to as PBSCM) and stored in ice until use.</p>1-2 [<sup>3</sup>H] 5-HT Uptake Test[<sup>3</sup>H]5-HT uptake was measured according to the method of Roman et al. [Roman D.L. et al., J. Pharmacol. Exp. Ther., 308, 679-687 (2004); and Hill A.V., J. Physiol., 40, 190-200 (1910)]. Specifically, 149 \u00b5l of the cell suspension (10\u00d710<sup>4</sup> cells/well) and 1 \u00b5l of a solution of a test drug dissolved in dimethyl sulfoxide were preincubated at 37\u00b0C for 10 minutes. Then, 50 \u00b5l of [<sup>3</sup>H] 5-HT (final concentration: approximately 10 nM) diluted with PBSCM was added thereto to prepare 200 \u00b5l in total of a solution. This solution was reacted at 37\u00b0C for 10 minutes and then rapidly filtered by suction at a low pressure through glass fiber filter paper coated with a 0.3% aqueous polyethyleneimine solution. The glass fiber filter paper was washed twice with 250 \u00b5l of an ice-cold saline and then transferred to a glass vial containing 4 ml of ACS-II (manufactured by Amersham Biosciences). Radioactivity remaining on the filter paper was measured using a liquid scintillation counter. The amount of [<sup>3</sup>H] 5-HT uptaken in the presence of 13.3 \u00b5M paroxetine was used as the amount of [<sup>3</sup>H]5-HT uptaken non-specifically.\nAn IC<sub>50</sub> value was calculated according to the Hill analysis [see Hill A.V., J. Physiol., 40, 190-200 (1910)]. An uptake inhibition constant (Ki) was calculated according to the following equation: U\u2062p\u2062t\u2062a\u2062k\u2062ei\u2062n\u2062h\u2062i\u2062b\u2062i\u2062t\u2062i\u2062o\u2062nc\u2062o\u2062n\u2062s\u2062tantKi=I\u2062C50/1+S/K\u2062m<img id=\"ib0049\" path=\"imgb0049.tif\" file=\"https://surechembl.org/api/assets/attachment/143494771/EP/20101013/A1/000002/23/92/54/imgb0049.tif\"/>\nwherein S represents the concentration of [<sup>3</sup>H]5-HT added; and the Km value represents the Michaelis constant of [<sup>3</sup>H]5-HT, wherein the Km value used was the value (441 nM) calculated by a saturation experiment separately conducted using the same cell preparation as above. The results are shown in Table 8.</p>[Table 8]Compound (Example No.)Test Example 5: h-SERT Function Inhibition Constant (Ki) [nM]18.921.644.261.6716104413511718</p>The test results of Table 8 demonstrated that the benzylpiperidine compound of the present invention or the pharmaceutically acceptable salt thereof acts on serotonin transporters in serotonergic neurons and thereby strongly inhibit serotonin reuptake.</p>Test Example 6X-Ray Powder Diffraction (XRPD) AnalysisAn X-ray powder diffraction (XRPD) analyzer used was X'Pert Pro manufactured by Spectris Co., Ltd. The measurement was conducted under conditions involving a diffraction angle (2\u03b8) in the range of 4\u00b0 to 40\u00b0, Cu K\u03b11 radiation (wavelength: 1.54060 \u00c5), an X-ray tube current of 40 mA, a voltage of 45 kV, a step of 0.01700\u00b0, and a measurement time of 101.41770 seconds/step. The measurement was conducted using approximately 5 mg of a sample in a non-reflective sample plate made of silicon single crystals (Si single crystals).\nEach crystal obtained in Examples 27 to 32 was subjected to the present analysis. The obtained X-ray powder diffraction patterns are shown in Figs. 1 to 6. Their crystal forms can be identified by determination from a diffraction peak characteristic of each crystal based on the diffraction pattern. The diffraction peak characteristic of each crystal identified from the diffraction pattern will be described later. In this context, a peak angle at the diffraction angle 2\u03b8 may have an error range to a certain degree depending on a measurement instrument or measurement conditions or the like. Specifically, a measureme"
]